Compare Recursion Pharmaceuticals Inc (RXRX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Target Corporation — how do they compare? Recursion Pharmaceuticals Inc trades at $4.25 (market cap $2.14B), while Target Corporation trades at $154.73 (market cap $70.31B). The key difference: Target Corporation is far larger — about 32.9× Recursion Pharmaceuticals Inc's market cap, and Target Corporation pays a 3% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Target Corporation for 137 Days on average.
| RXRX | TGT | |
|---|---|---|
Market Cap | $2.14B | $70.31B |
Volume | 30,789,535 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $169.90 |
52-Week Low | $2.84 | $83.68 |
Typical Hold Time | 22 Days | 137 Days |
Enterprise Value | $1.66B | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Target Corporation (TGT) trades at $154.56, up 2.38% with strong recent earnings beats and positive analyst sentiment. The stock shows bearish technical signals but maintains solid fundamentals with a 4.08% net margin and 26.41% ROE. Recent price cuts on 2,000 items aim to capture holiday market share, while consistent dividend payments reinforce shareholder returns. Valuation metrics appear reasonable with P/E of 16.05 and P/S of 0.65.
Target presents a balanced opportunity with analyst consensus pointing to 8% upside to the $167.18 price target. The turnaround strategy shows early success, but competitive pressures and margin compression from price investments remain key risks. Institutional support remains strong with 60 analyst coverage favoring buy/hold positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
